Spleen-preserving D2 subtotal distal resection of the stomach and corpocaudal resection of the pancreas after neoadjuvant induction chemotherapy and chemoradiotherapy: case report and literature review

Spleen-preserving D2 subtotal distal resection of the stomach and corpocaudal resection of the pancreas after neoadjuvant induction chemotherapy and chemoradiotherapy: case report and literature review

Background. Stomach cancer is one of the most common cancers worldwide. Long-term treatment outcomes in patients with locally advanced gastric cancer with invasion to adjacent structures are poor. In clinical recommendations of the Ministry of Health of the Russian Federation, it is recommended to t...

Full description

Bibliographic Details
Main Authors:	V. Yu. Skoropad, L. O. Petrov, D. D. Kudryavtsev, I. V. Kolobaev, E. S. Zhavoronkova, T. A. Agababyan
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Tomsk National Research Medical Center 2022-11-01
Series:	Сибирский онкологический журнал
Subjects:	locally advanced gastric cancer neoadjuvant chemotherapy neoadjuvant chemoradiotherapy therapeutic pathomorphosis surgical treatment
Online Access:	https://www.siboncoj.ru/jour/article/view/2321

Similar Items

Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis
by: Jiuzhou Chen, et al.
Published: (2022-08-01)

Assessment of the safety and feasibility of neoadjuvant chemotherapy (2 cycles of FLOT chemotherapy + chemoradiotherapy) followed by surgery in the treatment of locally advanced gastric cancer
by: D. Yu. Mironova, et al.
Published: (2024-03-01)

2-CONSERVATIVE TREATMENT OF RECTAL ADENOCARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY, IS IT ACCEPTABLE?
by: Majeed H Alwan
Published: (2009-06-01)

Clinical and morphological response to neoadjuvant chemotherapy followed by chemoradiotherapy in a patient with locally advanced gastric cancer: a case report
by: V. Yu. Skoropad, et al.
Published: (2023-06-01)

The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review
by: Dan Han, et al.
Published: (2022-07-01)

PATHOLOGICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED GASTRIC CANCER
by: V. Yu. Skoropad, et al.
Published: (2020-07-01)

Adjuvant Chemoradiotherapy Associated with Improved Overall Survival in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
by: Wing-Keen Yap, et al.
Published: (2022-11-01)

ANALYSIS OF HEMATOLOGIC, HEPATIC AND PANCREATIC TOXICITY DURING NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED GASTRIC CANCER
by: V. Yu. Skoropad, et al.
Published: (2018-07-01)

A Phase II Study of Neoadjuvant Chemoradiotherapy with Docetaxel, Cisplatin and 5-FU Followed by Surgical Resection in the Treatment of Locally Advanced Esophagogastric Junction Cancer and Locally Advanced Esophageal Cancer
by: Chien-Chih Chen, et al.
Published: (2024-04-01)

Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma
by: Guozhen Yang, et al.
Published: (2024-05-01)

Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study
by: Gaku Shimane, et al.
Published: (2024-12-01)

CANCER-EMBRYONIC ANTIGEN IN PREDICTING THERAPEUTIC TUMOR PATHOMORPHISM AFTER NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH RECTAL CANCER
by: D. V. Erygin, et al.
Published: (2018-06-01)

Neoadjuvant chemoradiotherapy in combined treatment of patients with rectal cancer
by: N. A. Maistrenko, et al.
Published: (2017-08-01)

The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma
by: Masaru Matsumura, et al.
Published: (2023-03-01)

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
by: Hai-Bo Sun, et al.
Published: (2020-04-01)

Retrospective Evaluation of the Efficacy of Total Neoadjuvant Therapy and Chemoradiotherapy Neoadjuvant Treatment in Relation to Surgery in Patients with Rectal Cancer
by: Lucian Dragoș Bratu, et al.
Published: (2024-04-01)

Impact of glucocorticoids on the efficacy of neoadjuvant chemoradiotherapy and survival of patients with locally advanced rectal cancer: a retrospective study
by: Xiaoxue Huang, et al.
Published: (2023-03-01)

Neoadjuvant chemotherapy in the combination treatment for locally advanced rectal cancer: currently available options
by: D. V. Kuzmichev, et al.
Published: (2018-11-01)

ASSESSMENT OF HISTOPATHOLOGICAL RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY IN GASTRIC CANCER PATIENTS: A MULTI-CENTER RANDOMIZED STUDY
by: V. Yu. Skoropad, et al.
Published: (2020-10-01)

Response Assessment after Neoadjuvant Chemoradiotherapy in Rectal Cancer
by: Anuradha Chandramohan, et al.

Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study
by: Jie Yang, et al.
Published: (2024-04-01)

Neoadjuvant Radiotherapy/Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
by: Deniz Yalman
Published: (2015-03-01)

Effect of circumferential resection margin status on survival and recurrence in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
by: Yi-Min Gu, et al.
Published: (2022-09-01)

Efficacy of modified neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A single institution experience in Taiwan
by: Yi-Ying Wu, et al.
Published: (2014-01-01)

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
by: Wenwu He, et al.
Published: (2022-06-01)

Preoperative chemoradiotherapy for locally advanced gastric cancer
by: Pepek Joseph M, et al.
Published: (2013-01-01)

Short- and long-term outcomes of neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy for locally advanced rectal cancer: an updated meta-analysis
by: Yue Guo, et al.
Published: (2025-02-01)

Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review
by: Xiao-Feng Duan, et al.
Published: (2014-09-01)

Neoadjuvant chemotherapy in localized resectable stomach cancer
by: Min-Hee Ryu
Published: (2014-06-01)

Local resection versus radical resection after neoadjuvant chemoradiotherapy for patients with locally advanced rectal cancer: a propensity-score matched cohort analysis
by: Guancong Wang, et al.
Published: (2023-06-01)

Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis
by: He Wang, et al.
Published: (2022-09-01)

Genetic prognostic factors for neoadjuvant chemoradiotherapy for colorectal cancer
by: V. A. Grigorenko, et al.
Published: (2021-07-01)

Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis
by: Yunsong Liu, et al.
Published: (2023-01-01)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
by: Hyun Hwan Sung, et al.
Published: (2022-03-01)

Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis
by: Zhaolun Cai, et al.
Published: (2018-08-01)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
by: Shigenori Ei, et al.
Published: (2023-09-01)

Laparoscopic total pelvic exenteration after neoadjuvant chemoradiotherapy for locally advanced rectal cancer
by: Chu-Ying Wu, et al.
Published: (2022-11-01)

Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study
by: Toshihiko Masui, et al.
Published: (2023-09-01)

The Expression of TP63 as a Biomarker of Early Recurrence in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
by: Chih-Hung Lin, et al.
Published: (2024-05-01)

Preoperative neoadjuvant chemoradiotherapy provides borderline resectable thoracic esophageal cancer with equivalent treatment results as clinically T3 thoracic esophageal cancer
by: Akiyuki Wakita, et al.
Published: (2023-11-01)